{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T17:15:55Z","timestamp":1770484555925,"version":"3.49.0"},"reference-count":29,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2016,9,1]],"date-time":"2016-09-01T00:00:00Z","timestamp":1472688000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["bprch.com","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice & Research Clinical Haematology"],"published-print":{"date-parts":[[2016,9]]},"DOI":"10.1016\/j.beha.2016.10.016","type":"journal-article","created":{"date-parts":[[2016,10,21]],"date-time":"2016-10-21T02:46:07Z","timestamp":1477017967000},"page":"264-270","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["NCCN and ELN: What do the guidelines tell us?"],"prefix":"10.1016","volume":"29","author":[{"given":"Kendra","family":"Sweet","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Javier","family":"Pinilla-Ibarz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.beha.2016.10.016_bib1","series-title":"NCCN Clinical practice guidelines in oncology chronic myelogenous leukemia","year":"2015"},{"issue":"122","key":"10.1016\/j.beha.2016.10.016_bib2","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","article-title":"European LeukemiaNet recommendations for the management of chronic myeloid leukemia","volume":"2013","author":"Baccarani","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.beha.2016.10.016_bib3","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1056\/NEJMoa022457","article-title":"Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia","volume":"348","author":"O'Brien","year":"2003","journal-title":"N.\u00a0Engl J Med"},{"key":"10.1016\/j.beha.2016.10.016_bib4","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1056\/NEJMoa1002315","article-title":"Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia","volume":"362","author":"Kantarjian","year":"2010","journal-title":"N.\u00a0Engl J Med"},{"key":"10.1016\/j.beha.2016.10.016_bib5","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1056\/NEJMoa0912614","article-title":"Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia","volume":"362","author":"Saglio","year":"2010","journal-title":"N.\u00a0Engl J Med"},{"key":"10.1016\/j.beha.2016.10.016_bib6","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1182\/blood-2006-02-004325","article-title":"Survival benefit with imatinib mesylate versus interferon-alpha-based regimens in newly diagnosed chronic-phase chronic myelogenous leukemia","volume":"108","author":"Kantarjian","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.beha.2016.10.016_bib7","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1182\/blood-2006-02-001495","article-title":"Survival advantage from imatinib compared with the combination interferon-alpha plus cytarabine in chronic-phase chronic myelogenous leukemia: historical comparison between two phase 3 trials","volume":"108","author":"Roy","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.beha.2016.10.016_bib8","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","article-title":"Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia","volume":"355","author":"Druker","year":"2006","journal-title":"N.\u00a0Engl J Med"},{"key":"10.1016\/j.beha.2016.10.016_bib9","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1182\/blood.V124.21.152.152","article-title":"Final study results of the phase 3 Dasatinib versus Imatinib in newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) trial (DASISION, CA180-056)","volume":"124","author":"Cortes","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.beha.2016.10.016_bib10","doi-asserted-by":"crossref","first-page":"4541","DOI":"10.1182\/blood.V124.21.4541.4541","article-title":"Efficacy and safety of nilotinib (NIL) vs imatinib (IM) in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): long-term follow-up (f\/u) of ENESTnd","volume":"124","author":"Larson","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.beha.2016.10.016_bib11","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1038\/sj.leu.2404388","article-title":"Rationale for the recommendations for harmonizing current methodology for detecting BCR-ABL transcripts in patients with chronic myeloid leukaemia","volume":"20","author":"Branford","year":"2006","journal-title":"Leukemia"},{"key":"10.1016\/j.beha.2016.10.016_bib12","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1200\/JCO.2011.38.6565","article-title":"Assessment of BCR-ABL1 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors","volume":"30","author":"Marin","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.beha.2016.10.016_bib13","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1038\/leu.2012.85","article-title":"Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML)","volume":"26","author":"Hanfstein","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.beha.2016.10.016_bib14","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1182\/blood-2014-03-566323","article-title":"Prognosis for patients with CML and >10% BCR-ABL1 after 3 months of imatinib depends on the rate of BCR-ABL1 decline","volume":"124","author":"Branford","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.beha.2016.10.016_bib15","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1182\/blood-2013-06-511592","article-title":"Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION)","volume":"123","author":"Jabbour","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.beha.2016.10.016_bib16","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1182\/blood-2013-06-510396","article-title":"Early molecular response predicts outcomes in patients with chronic myeloid leukemia in chronic phase treated with frontline nilotinib or imatinib","volume":"123","author":"Hughes","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.beha.2016.10.016_bib17","doi-asserted-by":"crossref","first-page":"4867","DOI":"10.1182\/blood-2013-03-490128","article-title":"Early responses predict better outcomes in patients with newly diagnosed chronic myeloid leukemia: results with four tyrosine kinase inhibitor modalities","volume":"121","author":"Jain","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.beha.2016.10.016_bib18","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.3324\/haematol.2013.091272","article-title":"Safety and efficacy of switching to nilotinib 400\u00a0mg twice daily for patients with chronic myeloid leukemia in chronic phase with suboptimal response or failure on front-line imatinib or nilotinib 300\u00a0mg twice daily","volume":"99","author":"Hughes","year":"2014","journal-title":"Haematologica"},{"key":"10.1016\/j.beha.2016.10.016_bib19","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1182\/blood-2013-12-544015","article-title":"Deep molecular responses achieved in patients with CML-CP who are switched to nilotinib after long-term imatinib","volume":"124","author":"Hughes","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.beha.2016.10.016_bib20","doi-asserted-by":"crossref","first-page":"4541","DOI":"10.1182\/blood-2011-04-348110","article-title":"The achievement of an early complete cytogenetic response is a major determinant for outcome in patients with early chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitors","volume":"118","author":"Jabbour","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.beha.2016.10.016_bib21","doi-asserted-by":"crossref","first-page":"4250","DOI":"10.1182\/blood-2005-11-4406","article-title":"BCR-ABL mRNA levels at and after the time of a complete cytogenetic response (CCR) predict the duration of CCR in imatinib mesylate-treated patients with CML","volume":"107","author":"Press","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.beha.2016.10.016_bib22","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1200\/JCO.2010.32.0598","article-title":"Tolerability-adapted imatinib 800\u00a0mg\/d versus 400\u00a0mg\/d versus 400\u00a0mg\/d plus interferon-alpha in newly diagnosed chronic myeloid leukemia","volume":"29","author":"Hehlmann","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.beha.2016.10.016_bib23","doi-asserted-by":"crossref","first-page":"3358","DOI":"10.1200\/JCO.2007.15.8154","article-title":"Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis","volume":"26","author":"de Lavallade","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.beha.2016.10.016_bib24","doi-asserted-by":"crossref","first-page":"4437","DOI":"10.1182\/blood-2008-06-162388","article-title":"European LeukemiaNet criteria for failure or suboptimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poor","volume":"112","author":"Marin","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.beha.2016.10.016_bib25","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1038\/leu.2011.355","article-title":"Nilotinib is effective in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blastic phase","volume":"26","author":"Giles","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.beha.2016.10.016_bib26","doi-asserted-by":"crossref","first-page":"2176","DOI":"10.1038\/leu.2008.221","article-title":"Efficacy and safety of dasatinib in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blast phase","volume":"22","author":"Cortes","year":"2008","journal-title":"Leukemia"},{"key":"10.1016\/j.beha.2016.10.016_bib27","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1182\/blood-2012-03-380147","article-title":"How I treat CML blast crisis","volume":"120","author":"Hehlmann","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.beha.2016.10.016_bib28","doi-asserted-by":"crossref","first-page":"2791","DOI":"10.1182\/blood-2006-04-019836","article-title":"Prophylactic administration of imatinib after hematopoietic cell transplantation for high-risk Philadelphia chromosome-positive leukemia","volume":"109","author":"Carpenter","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.beha.2016.10.016_bib29","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1182\/blood.V114.22.1126.1126","article-title":"International randomized study of interferon vs STI571 (IRIS) 8-Year follow up: sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib","volume":"114","author":"Deininger","year":"2009","journal-title":"Blood"}],"container-title":["Best Practice & Research Clinical Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S152169261630069X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S152169261630069X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,9,26]],"date-time":"2020-09-26T20:51:32Z","timestamp":1601153492000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S152169261630069X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9]]},"references-count":29,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016,9]]}},"alternative-id":["S152169261630069X"],"URL":"https:\/\/doi.org\/10.1016\/j.beha.2016.10.016","relation":{},"ISSN":["1521-6926"],"issn-type":[{"value":"1521-6926","type":"print"}],"subject":[],"published":{"date-parts":[[2016,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"NCCN and ELN: What do the guidelines tell us?","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Haematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.beha.2016.10.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}